Prescriber treatment patterns for tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin (mTOR) inhibitors in patients with renal cell carcinoma.
The 2026 European Association of Urology (EAU) annual meeting featured a managing advanced disease in renal and rare cancer ...
Lung metastases are most common in clear cell renal cell carcinoma, whereas lymph node metastases and liver metastases occur most frequently in papillary and chromophobe RCC, respectively, ...
The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, discussing three abstracts, “Belzutifan + lenvatinib versus cabozantinib for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results